anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Acetyl mannan has molecular weight of 5,000-200,000 and its molecular skeleton is mannopyranose connected by beta-D-(1-4) glucosidic bond. In its structure, there are acetyl groups led to C2, C3 and C6 hydroxy positions of carbon cycle and in the amount of 40-95% manno groups. Plant gelatin of average molecular weight over 200,000 is reacted in the catalysis of proper amount of beta-mannase, and the high-purity mannan is purified through ethanol precipitation and other process and acetylated with acetic acid, acetate anhydride anjd other reagent. Acetyl mannan is one kind of efficient immunopetentiator with the functions of inhibiting tumor growth, promoting wound heal, resisting infection, etc. and no toxic side effect. It may be mass prepared through acetylating plant mannan.
Patients randomized to the experimental arm will receive 3 days of 0.5 mg of varenicline, followed by 4 days of 1 mg of varenicline (until day 7). Finally, until week 12, they will receive 2 mg of varenicline. Varenicline is supplied in capsules and taken orally.
Patients undergo radiotherapy comprising pelvic external beam radiotherapy daily five days a week for 5 weeks, followed by either 1 or 2 implants of low-dose rate intracavitary brachytherapy or 5 fractions of high-dose rate intracavitary brachytherapy, followed by 3-5 days of parametrial boost radiotherapy. Patients receive cisplatin IV concurrently with pelvic external beam radiotherapy on days 1, 8, 15, 22, 29, and once during the week of parametrial boost radiotherapy.
This study will aim to enroll approximately 100 patients with Crohn Disease (CD). All patients who have CD will be evaluated at the Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Patients who are eligible for the study will be identified during these regularly scheduled clinic visits. Patients and guardians who express interest will be set up for a meeting with a clinical research coordinator who will go over the study in detail and will obtain informed consent. Before the therapeutic intervention，stool samples will be checked for ova and parasites, C. difficile toxin and fecal calprotectin (FCP). Serum tests will include erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Anti-nuclear antibodies (ANA), complete blood cell count, HIV, screening for Hepatitis A, B, C (hep A IgM, hep B surface antigen and antibody, Hep C antibody), and creatinine. Fecal tests included 16S rDNA flora detection and metabolite detection. Patients with CD will undergo colonoscopy, which is considered part of standard of care for patients with ongoing inflammation and is not considered a study procedure.

Dynamic monitoring follow-up up to 102 weeks, dynamic assessment of relevant indicators, such as ESR, CRP, FCP and endoscopy, etc. This study is an observational study, without intervention in the treatment of patients. Patients will accept the treatment plan formulated by the attending physician. Treatment options include: enteral nutrition (EEN/ PEN, reason, route of administration, dose, course of treatment); glucocorticoids (reason, route of administration, dose, course of treatment); immunosuppressants (reason, route of administration, dose, course of treatment); biologics (including domestic infliximab (Taizhou Mabtech Pharmaceutical Co.,Ltd)) (dose, duration, effectiveness, safety, and economy); fecal microbiota transplantation (cause, transplantation routes, capsule fecal transplants, dose, course of treatment); the medical costs and resource consumption of the treatment of Crohn's disease in children. The difference of efficacy of the above treatment schemes was recorded, the treatment outcome was compared, and the transformation of treatment schemes was discussed. Researchers and patients will truthfully register the corresponding data generated by clinical practice from the doctors and patients respectively, collect the laboratory examination and evaluation data of doctors during the visit, and combine the hospital visit and electronic information system. Statistical analysis was performed after follow-up.
This is a single site, non-randomized study. The study consists of a Screening Visit (Visit 1) during which the subject will be consented and the inclusion exclusion criteria confirmed. An interventional visit (Visit 2)which consists of a 72 hour in-clinic stay and a Follow-up Visit (Visit 3). Subjects eligible for the study will be admitted to the clinic for the Study Visit 2 in the afternoon on the day before the first Clamp is performed. An IV line for blood sampling will be established. One blood sample will be obtained for glucose determination and a second blood sample will be collected for immunoassay development before any sensors are inserted. Two BD-Glucose Binding Protein-Continuous Glucose Monitor Sensors(BD-GBP-CGM), with and without outer layer, and one commercial CGM sensor will be inserted in the subcutaneous tissue in the abdomen shortly thereafter. Blood sampling intervals will be adjusted over the 3 study days as determined by the study event (i.e. clamp period, meal excursion, nighttime). During the hyper- /hypo-glycemic clamps periods on Day 1 and Day 3 blood samples will be taken more frequently, every 5-10 minutes. During the breakfast meal on Day 2 sampling will occur at 10-15 minute intervals for 4 hours to capture the meal excursion. Sampling will be less frequent during the evening meal and at night during sleep hours.
This group of children will not receive Walk Aide training during the first six weeks of enrollment. This group will serve as a comparator group to Arm 1. After six weeks, children in this group will be given the option to complete the 6-week Walk Aide training protocol that is given in Arm 1.
The intervention will consist of two components: education and an electronic prompt via the iOS application Stand Up and notification through the Amzafit BIP device. The Stand-Up application will generate a prompt every hour during the workday to interrupt sitting time and encourage 2 minutes of physical activity. The intervention group participants will be given verbal and written educational materials on the health benefits of incorporating physical activity throughout their workday as well as the health risks of a sedentary lifestyle. Suggestions and demonstrations of physical activity will be given including but not limited to: use a restroom further away from their workstation, take a brief walk around the office, walk-in place, stretch. In addition, they will record their steps via the Amazfit BIP device and submit their daily step counts for weeks: 1,2,4, 6 and 8.
Children are assessed and treated according to the WHO and UNICEFs paper-based Community Case Management decision aid for Malawi for a minimum of 2 and a maximum of 7-weeks. Clinical assessment is guided by the paper-based 'Sick Child Form' presented in English, and clinical data is recorded by Health Surveillance Assistants manually in the Village Clinic Register.
NEW MATERIAL:A benzimidazole derivative shown by the formula I (R and R<1> are H, lower alkoxy, or halogen; R<2> is benzyloxy which is replaced with lower alkoxy, etc., on occasion), or its acid addition salt. EXAMPLE:2-[2-(4-Benzyloxy)pyridylmethylsulfinyl]benzimidazole. USE:A remedy for gastric ulcer or duodenal ulcer. Having stronger inhibitory action on secretion of acid in the stomach than omeprazole. PREPARATION:A 2-mercaptobenzimidazole derivative shown by the formula II is reacted with a substituted pyridine derivative shown by the formula III (X is halogen, or reactive ester residue) or its acid addition salt in a solvent such as THF, etc., to give a 2-(substituted pyridylmethylthio)benzimidazole shown by the formula IV. Then the compound shown by the formula IV is oxidized with an oxidizing agent such as an aqueous solution of hydrogen peroxide, to give a compound shown by the formula I.
PURPOSE: A composition for promoting differentiation of human mesenchymal stem cells to adipocytes is provided to enhance volume and elasticity and to ensure anti-wrinkle effect. CONSTITUTION: An external composition for promoting adipocyte differentiation contains extract of Spatholobus suberectus Dunn., Alpinia officinarum Hance, Angelica pubescens for. biserrata Shan Etyuan, or Melia azedarach var. japonica Makino as an active ingredient. The composition promotes differentiation of mesenchymal stem cells to adipocytes. The mesenchymal stem cell is human mesenchymal stem cell. The composition contains the extract in 0.0001-30 weight% based on total weight. The composition enhances skin volume and elasticity.
Post-translational modifications (PTMs) have emerged as pivotal regulators of the development of cancers, including esophageal squamous cell carcinoma (ESCC). Here, we conducted a comprehensive analysis of PTM-related genetic variants associated with ESCC risk using large-scale genome-wide and exome-wide association datasets. We observed significant enrichment of PTM-related variants in the ESCC risk loci and identified five variants that were significantly associated with ESCC risk. Among them, rs6780013 in PTPN23 exhibited the highest level of significance in ESCC susceptibility in 9,728 ESCC cases and 10,977 controls (odds ratio [OR] = 0.85, 95 % confidence interval [CI] = 0.81- 0.89, P = 9.77 × 10-14). Further functional investigations revealed that PTPN23[Thr] variant binds to EGFR and modulates its phosphorylation at Thr699. PTPN23[Thr] variant substantially inhibited ESCC cell proliferation both in vitro and in vivo. Our findings underscore the critical role of PTPN23[Thr]-EGFR interaction in ESCC development, providing more insights into the pathogenesis of this cancer.
PROBLEM TO BE SOLVED: To obtain a stabilized vitamin C composition containing an active anti-oxidation substance contained in a green leaf component of a green plant. SOLUTION: This composition is obtained by compounding 2''-O-glucolsyl- isovitexine of the structure of the formula in an amount of 0.01-5mol, preferably 0.05-2mol based on 1mol of vitamin C in terms of the compound of the formula. The compound of the formula is obtained as follows. A green juice is prepared by squeezing a green plant belonging to a group of wheat such as barley, preferably fresh stalks and/or leaves of a voung plant harvested before maturity, by a juicer, etc. This juice is dried to obtain powdery material. The green juice or the powder is extracted with water or n-hexane. Water soluble opart or a part substantially insoluble in n-hexance is recovered.  The water-soluble part or the n-hexane insoluble part is extatctid with a hydrated alcohol containing 0-80% water, and the component soluble in the hydratecd alcohol is recevered follwed by recrystallization and putification to obtain an active anti-oxidation compound of the formula. The substance can be used for foods such as vairious drinks, sweet and candies, medicines quasi-drugs, etc.
The present invention relates to a radioactive radiation source in form of a wire comprising a matrix of a ductile and/or plastic bindermaterial and a radioactive and/or activatable material.  Preferably the elastic bindermaterial is a metal, a metal alloy or a radiation resistant plastic material or mixture thereof. The radioactive or then activated activatable material is a .beta.-emitter, a .gamma. emitter or x-ray emitter. The source may further comprise a means for containment. The radioactive radiation source of the invention is preferably used in intravascular radiation treatment e.g. to treat cancer, tumours, non-malign cell growth, or scar tissue or to prevent restenosis.
An osmotic delivery system having a space-efficient piston is provided. The enclosure has an interior holding the piston, a beneficial agent, and an osmopolymer including a tablet. The piston is movable with respect to an interior surface of the capsule, and defines a movable seal with the interior surface of the capsule. The movable seal separates the osmopolymer from the beneficial agent. The piston has a recess that receives at least a portion of the osmopolymer. The osmopolymer imbibes liquid from a surrounding environment through a semipermeable body to cause the piston to move and, in turn, cause delivery of the beneficial agent from the capsule.
A cosmetic raw material provides uniform dispersions of silicone oils and crosslinked silicone particles in cosmetic products. The cosmetic products consist of the cosmetic raw material combined with other types of cosmetic raw materials. This provides pleasant sensations of touch with the fingers and skin, improved rubbing properties, and sensation in their use. The method of manufacturing the cosmetic products has a high efficiency. The cosmetic raw material is made from a silicone oil emulsion containing crosslinked silicone particles having an average diameter of 0.05-100 μm which are contained in silicone oil drops having an average diameter of 0.1-500 μm, the drops in turn being dispersed in water. The diameter of the crosslinked silicone particles is less than the diameter of the silicone oil drops.
BACKGROUND: Retinal degeneration results from disruptions in retinal homeostasis due to injury, disease, or aging and triggers peripheral leukocyte infiltration. Effective immune responses rely on coordinated actions of resident microglia and recruited macrophages, critical for tissue remodeling and repair. However, these phagocytes also contribute to chronic inflammation in degenerated retinas, yet the precise coordination of immune response to retinal damage remains elusive. Recent investigations have demonstrated that phagocytic cells can produce extracellular traps (ETs), which are a source of self-antigens that alter the immune response, which can potentially lead to tissue injury.
METHODS: Innovations in experimental systems facilitate real-time exploration of immune cell interactions and dynamic responses. We integrated in vivo imaging with ultrastructural analysis, transcriptomics, pharmacological treatments, and knockout mice to elucidate the role of phagocytes and their modulation of the local inflammatory response through extracellular traps (ETs). Deciphering these mechanisms is essential for developing novel and enhanced immunotherapeutic approaches that can redirect a specific maladaptive immune response towards favorable wound healing in the retina.
RESULTS: Our findings underscore the pivotal role of innate immune cells, especially macrophages/monocytes, in regulating retinal repair and inflammation. The absence of neutrophil and macrophage infiltration aids parenchymal integrity restoration, while their depletion, particularly macrophages/monocytes, impedes vascular recovery. We demonstrate that macrophages/monocytes, when recruited in the retina, release chromatin and granular proteins, forming ETs. Furthermore, the pharmacological inhibition of ETosis support retinal and vascular repair, surpassing the effects of blocking innate immune cell recruitment. Simultaneously, the absence of ETosis reshapes the inflammatory response, causing neutrophils, helper, and cytotoxic T-cells to be restricted primarily in the superficial capillary plexus instead of reaching the damaged photoreceptor layer.
CONCLUSIONS: Our data offer novel insights into innate immunity's role in responding to retinal damage and potentially help developing innovative immunotherapeutic approaches that can shift the immune response from maladaptive to beneficial for retinal regeneration.
Peritoneal dialysis is an important part of end-stage kidney disease replacement therapy. However, prolonged peritoneal dialysis can result in peritoneal fibrosis and ultrafiltration failure, forcing patients to withdraw from peritoneal dialysis treatment. Therefore, there is an urgent need for some effective measures to alleviate the occurrence and progression of peritoneal fibrosis. Mesenchymal stem cells play a crucial role in immunomodulation and antifibrosis. Numerous studies have investigated the fact that mesenchymal stem cells can ameliorate peritoneal fibrosis mainly through the paracrine pathway. It has been discovered that mesenchymal stem cells participate in the improvement of peritoneal fibrosis involving the following signaling pathways: TGF-β/Smad signaling pathway, AKT/FOXO signaling pathway, Wnt/β-catenin signaling pathway, TLR/NF-κB signaling pathway. Additionally, in vitro experiments, mesenchymal stem cells have been shown to decrease mesothelial cell death and promote proliferation. In animal models, mesenchymal stem cells can enhance peritoneal function by reducing inflammation, neovascularization, and peritoneal thickness. Mesenchymal stem cell therapy has been demonstrated in clinical trials to improve peritoneal function and reduce peritoneal fibrosis, thus improving the life quality of peritoneal dialysis patients.
PROBLEM TO BE SOLVED: To obtain the subject composition enabling efficient intake of docosahexaenoic acid(DHA) by formulating a linoleic fatty acid with an α- linolenic faty acid in a specific proportion. SOLUTION: This composition is obtained by including (A) a linoleic fatty acid [n-6, 18:2] and (B) an α-linolenic fatty acid [n-3, 18:3]. In the above composition, the abundance ratio (weight ratio) of the ingredients A to B is the ingredients A/B=0.05-7.5. Since the composition is capable of increasing the amount of the DHA in the brain of an animal administered with the composition, the composition has effects on enhancement of recognition power (learning power) or memory retaining power. The daily dose of the composition is preferably 9-18 g based on 60 kg body weight. The ingredients A and B are obtained from a flax oil, e.g. a flax powder, flax seed meal or a flax seed oil, a perilla oil, etc.
FIELD: medicine. SUBSTANCE: method involves an extraction of ginseng leaves of different age with 20-50% an aqueous ethanol at ratio raw : extractant = 1:(10-14) for 8-11 h. Extract is settled and filtered. Complex shows the enhanced adaptogenic effect as compared with ginseng root tincture and also HYPOGLYCEMIC, antiinflammatory and antihypoxic effects. Complex is not toxic. EFFECT: improved method of preparing, enhanced effectiveness. 5 tbl
Increasing water stress is emerging as a global phenomenon, and is anticipated to have a marked impact on forest function. The role of tree functional strategies is pivotal in regulating forest fitness and their ability to cope with water stress. However, how the functional strategies found at the tree or species level scale up to characterise forest communities and their variation across regions is not yet well-established. By combining eight water-stress-related functional traits with forest inventory data from the USA and Europe, we investigated the community-level trait coordination and the biogeographic patterns of trait associations for woody plants, and analysed the relationships between the trait associations and climate factors. We find that the trait associations at the community level are consistent with those found at the species level. Traits associated with acquisitive-conservative strategies forms one dimension of variation, while leaf turgor loss point, associated with stomatal water regulation strategy, loads along a second dimension. Surprisingly, spatial patterns of community-level trait association are better explained by temperature than by aridity, suggesting a temperature-driven adaptation. These findings provide a basis to build predictions of forest response under water stress, with particular potential to improve simulations of tree mortality and forest biomass accumulation in a changing climate.
Heart failure (HF) is a major public health problem worldwide. As the final common pathway of a myriad of heart diseases, HF burden increases with increasing prevalence of cardiovascular disease in a community, as patients survive their acute cardiac conditions (such as heart attacks) and progress to chronic HF. Further, HF is a debilitating and deadly condition with high rehospitalization rates and dismal survival rates comparable to most cancers. In Singapore alone, the age-adjusted HF admission rate rose by \~40% over the last decade,1 making HF the commonest cardiac cause of hospitalization (representing \~24% of all cardiac admissions), and the 5-year survival rate in patients with HF is only 32%. These alarming statistics reflect the global shift in cardiovascular disease burden to developing countries in Asia. In fact, the World Health Organization has projected that the largest increases in cardiovascular disease worldwide are occurring in Asia, due to rapidly increasing rates of smoking, obesity, dyslipidemia and diabetes among Asians. Thus the burden of HF is expected to reach epidemic proportions in Asia. Yet in sharp contrast to the wealth of data regarding HF in Western nations, epidemiologic data are scarce in Asian patients with HF.

The study will involve 46 top medical centers across 11 Asian regions (Korea, Thailand, Indonesia, Philippines, India, Japan, Malaysia, Hong Kong, China, Taiwan and Singapore). Site selection targeted a mix of centers covering a broad spectrum of medical, cardiology and HF specialty units regularly admitting patients with acute HF and following outpatients with chronic HF, constituting a novel network of Asian centers of cardiovascular expertise.

Data collection will include demographic variables, clinical symptoms, functional status, date of HF diagnosis and prior cardiovascular investigations, clinical risk factors, lifestyle factors, socioeconomic status, and survey of cultural beliefs, health practices and attitudes towards device therapy. Center-level characteristics (caseload, referral pattern, specialization, infrastructure) will also be obtained. Patients will undergo standard 12-lead electrocardiography and transthoracic echocardiography at baseline, and followed over 3 years for outcomes of death or hospitalization. Each outcome event and its cause will be adjudicated by a central committee using pre-specified criteria.
A method for preparing hydro/organo gelators from disaccharide sugars by biocatalysis and their use in enzyme-triggered drug delivery. Controlled delivery of an anti-inflammatory, chemopreventive drug is achieved by an enzyme-triggered drug release mechanism via degradation of encapsulated hydrogels. The hydro- and organo-gelators are synthesized in high yields from renewable resources by using a regioselective enzyme catalysis and a known chemopreventive and anti-inflammatory drug, curcumin, is encapsulated in the gel matrix and released by enzyme triggered delivery. The release of the drug occurs at the physiological temperature and control of the drug release rate is achieved by manipulating the enzyme concentration and temperature. The by-products formed after the gel degradation clearly demonstrated the site specificity of degradation of the gelator by enzyme catalysis. The present invention has applications in developing cost effective, controlled drug delivery vehicles from renewable resources, with a potential impact on pharmaceutical research and molecular design and delivery strategies.
Providers allocated to intervention will automatically see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.